Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of BI 425809 in Healthy Male Subjects
NCT02068690Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Mar 2014
- Primary completion
- Sep 2014
- Modality
- Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of iclepertin in schizophrenia (16 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Number of Participants With Drug-related Adverse Events up to 18 days. Started Mar 2014; status: completed.
02
Drugs
iclepertin
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT02068690.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02068690.